Septerna (SEPN) had its price target raised by Wells Fargo & Company from $28.00 to $48.00. They now have an "overweight" rating on the stock.
Septerna (SEPN) had its price target raised by HC Wainwright from $35.00 to $40.00. They now have a "buy" rating on the stock.
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy [Yahoo! Finance]
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy
Septerna (SEPN) was upgraded by Zacks Research from "strong sell" to "hold".